Objective. The incidence and prevalence of gout are increasing, but the management is poor. Considering the increased prevalence of gout in the diabetic population, this study evaluated the effects of pioglitazone, an insulin resistance inhibitor, on the incidence of gout in the diabetic population.
Introduction
The prevalence and incidence of gout have distinct geographical, racial, lifestyle and comorbidity distributions [1] .The prevalence of gout is > 1% in most developed countries, including North America and Europe [1, 2] . However, the prevalence rate in Oceanian countries is estimated to be >10% [36] . A study published in 2010 reported that only approximately one-fifth of the individuals with gout were prescribed urate-lowering treatment (ULT) [7] . Despite increasing awareness regarding gout, limited medications, including allopurinol, benzbromarone, probenecid, sulfinpyrazone and febuxostat, are available for ULT [8] . Gout is not considered a simple joint disease. It is associated with metabolic syndrome (MetS) and increased mortality; it may also warrant treatment for an associated metabolic disorder and often some modification of gout management [911] . The risk factors for gout include obesity, hypertension, type 2 diabetes mellitus, MetS, chronic kidney disease (CKD), lifestyle factors and increased usage of causative medications [12] . Insulin resistance (IR) and MetS are the main factors for severe sequelae associated with gouty arthritis [13] . Metformin and peroxisome proliferator-activated receptor gamma (PPAR-g) agonist were both used for diabetes control through IR reduction [14, 15] . Previous studies have reported that in diabetic patients with IR reduction, thiazolidinediones (TZDs), such as pioglitazone, can prevent many comorbidities, including cerebrovascular disease (CVD) [15] , secondary CVD [16] , coronary artery disease (CAD) [17] and restenosis after coronary stenting [18] , and can contribute renoprotection to patients with diabetic nephropathy [19] . However, no nationwide human study has evaluated the effect of pioglitazone on gout incidence. We designed this study to investigate the incidence of new-onset gout in TZD (pioglitazone) and comparison cohorts.
Methods

Data sources
Taiwan launched a single-payer National Health Insurance (NHI) programme on 1 March 1995. The data used in this study were derived from the Longitudinal Cohort of Diabetes Patients. Insurance claims data, including detailed files of outpatient, emergency, inpatient and pharmacy treatment records from 1 January 1996 to 31 December 2013 of patients with a diagnosis of diabetes were extracted from the records of the Bureau of NHI. This sample comprised 120 000 new diabetic patients who were randomly selected by the system every year from 1 January 1999 to 31 December 2012. The Longitudinal Cohort of Diabetes Patients provides encrypted data of patient identification numbers, sex, date of birth, dates of admission and discharge; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes of diagnoses and procedures; details from prescriptions and the registry of the Catastrophic Illness Patient Database; and costs covered and paid for by the NHI programme. The Institutional Review Board of Kaohsiung Medical University approved the protocol for this study (KMUHIRB-EXEMPT(II)-20150069). Informed consent was not required because the datasets were devoid of identifiable personal information.
Study sample
During the recruitment period of 200005, a retrospective cohort study was conducted with two study groups: a pioglitazone user cohort and a matched non-pioglitazone user cohort that was used as a control for comparison (Fig. 1) . Pioglitazone users were defined as those with at least two outpatient service claims with the Anatomical Therapeutic Chemical (ATC) code of AB03 (ICD-9-CM code 250 for diabetes mellitus) at any hospital or local medical clinic or any one hospitalization with diabetes listed among the claims diagnosis codes and with pioglitazone use. Patients diagnosed as having diabetes before 2000 were excluded. We excluded patients who were <20 years of age and who had incomplete demographic data. Because the outcome of interest was the new onset of gout, any patient with a diagnosis of gout (ICD-9-CM code 274) before the index date (diagnosis of diabetes) was excluded. Because insulin increases IR [17] , we excluded patients with insulin use. For each pioglitazone user, three non-pioglitazone users were randomly selected from the dataset as a control group match. Pioglitazone users were matched with members of the control group by hypertension, age, hyperlipidaemia, CAD, monthly income, area of residence and index date. The index date for each pioglitazone user was the date of that user's first registration. The year of that index date was used to create the index date for each comparison subject.
Demographic data such as sex, age, geographic location within Taiwan and monthly income [recorded in new Taiwan dollars (NT$)] were collected. Baseline comorbidities of these patients were also recorded. These included hypertension (ICD-9-CM codes 401405), CAD (ICD-9-CM codes 410414) and hyperlipidaemia (ICD-9-CM codes 272), which are known to affect the risk of gout. We defined any of these comorbid conditions to be present if there were three or more ambulatory care events coded 1 year before the index medical care date or the condition was diagnosed in an inpatient setting. The follow-up period in person-years was calculated for each person until the diagnosis of diabetes, death, or the end of 2011.
Measurements of pioglitazone
Commercially available pioglitazone [AC50043100, AC56692100 (15 mg), B023206100 (30 mg)] in Taiwan was analysed. According to the total supply in days and quantity of pioglitazone, we calculated the cumulative defined daily dose (DDD) of pioglitazone for each pioglitazone user. For pioglitazone, the cumulative pioglitazone use was partitioned into three levels at the 33rd and 67th percentiles. The DDD was defined by the Anatomical Therapeutic Chemical Classification System (ATC)/DDD system from the World Health Organization's Collaborating Center for Drug Statistics and Methodology. Each product should be referred to by the appropriate ATC code and DDD. The unit of DDD was defined as the assumed average maintenance dose per day for a drug used for its major indication in adults. This could provide a fixed unit of measurement independent of the price and dosage form, thus the trends in drug consumption could be assessed and comparisons between population groups could be performed. Through standardization of the drug dose across multiple types of drugs, trends could be compared. The number of DDDs was calculated as the total amount of drugs divided by the amount of drug in a DDD. The cumulative DDD, which expresses the https://academic.oup.com/rheumatology dosage and duration of exposure, could be used to estimate the sum of the dispensed DDD of pioglitazone. Thus we could correlate pioglitazone use and new-onset gout risk in diabetic patients by using the cumulative DDD.
Statistical analysis
All statistical operations were performed using SPSS software, version 19 (IBM, Armonk, NY, USA). Pearson's chisquare test was used to compare the differences in the baseline characteristics, comorbidities and sociodemographic status between the study and control cohorts. The incidence rate was calculated as the number of newly diagnosed gout cases during the follow-up period divided by the total person-years for each group by age and duration. The risk of new-onset gout was compared between the pioglitazone users and the non-pioglitazone users by estimating the incidence rate ratio through Poisson regression. Moreover, stratified Cox proportional hazards regression analysis (stratified by age group: <40, 4059 and 560 years) was used to compute the adjusted hazards ratios for the new onset of gout between patients with and without pioglitazone use, after adjusting for possible confounding factors (geographic area, monthly income, hypertension, CAD, hyperlipidaemia). We use KaplanMeier analysis to calculate the cumulative incidence rates of new-onset gout between the two cohorts and the log-rank test was used to analyse the differences between the survival curves. A two-sided P-value <0.05 was considered significant.
Results
Patient characteristics
Among the diabetic patients without gout, we identified 30 100 pioglitazone users and 90 300 non-pioglitazone users between the years 2005 and 2009 (Fig. 1) . The distributions of sex and age at entry were the same in both groups (Table 1) . Females accounted for 52.4% of the patients among both the pioglitazone users and non-pioglitazone users. The mean age of the pioglitazone users was 58.22 years (S.D. 11.87) and that of the non-pioglitazone users was 58.33 years (S.D. 11.96). Compared with participants without pioglitazone use, those with pioglitazone use had the same prevalence of hypertension, hyperlipidaemia, CAD, CVD and CKD.
The results of the log-rank test and cumulative incidence curve for the new onset of gout events are shown in Fig. 2 . The findings indicated that the pioglitazone users exhibited a significantly lower incidence rate for the new onset of gout than did the non-pioglitazone users (P < 0.001). During an average of 4.48 years of follow-up, 8917 non-pioglitazone users and 2457 pioglitazone users exhibited new-onset gout ( Table 2 ). The new-onset gout average duration ( Table 2 we show the doseresponse relationship between pioglitazone use and the risk of new-onset gout. We also compare the incidence of new-onset gout between pioglitazone users compared with non-pioglitazone users. The overall incidence of gout was 21.08/1000 person-years and the incidence of gout was 17.94/1000 person-years in pioglitazone users and 22.15/1000 person-years in non-pioglitazone users. Among pioglitazone users, the adjusted hazard ratio (aHR) was 0.81 (95% CI 0.78, 0.85; P < 0.001) for all, 0.83 (95% CI 0.77, 0.89; P < 0.001) for those with a cumulative DDD <267, 0.84 (95% CI 0.79, 0.90; P < 0.001) for those with a cumulative DDD of 267707 and 0.77 (95% CI 0.71, 0.82; P < 0.001) for those with a cumulative DDD 5708. The higher the cumulative DDD of pioglitazone use, the more significant the risk reduction for new-onset gout (P for trend <0.001).
Multivariate analysis
Sex stratification indicated that male and female pioglitazone users both had a significant risk reduction for newonset gout compared with those without pioglitazone use [males: aHR 0.80 (95% CI 0.75, 0.85; P < 0.001); females: aHR 0.83 (95% CI 0.78, 0.88; P < 0.001)]; Table 4 
Discussion
Our study demonstrated that the incidence rate for newonset gout is lower in diabetic patients with pioglitazone use than in those without pioglitazone use. The higher the cumulative dose of pioglitazone used, the more significant the risk reduction for new-onset gout. A significantly longer duration of new-onset gout was observed among pioglitazone users than among non-pioglitazone users. Hyperuricaemia patients with gout are correlated with MetS. IR may provide clues to better understand the relationship between gout and MetS [20] . The prevalence of MetS is not only high among patients with gout [21] but is also significantly increased with the serum uric acid (SUA) level and risk of CKD [22] . The harmonized MetS definition for Asians, including Taiwanese, consists of having three or more of the following risk factors: elevated fasting glucose >100 mg/dl or the current use of any antidiabetic medication, elevated triglyceride (5150 mg/dl), highdensity lipoprotein <40 mg/dl in men and <50 mg/dl in women, elevated blood pressure (BP; systolic BP 5130 mmHg or diastolic BP 585 mmHg or the current use of any anti-hypertensive medication) and increased waist circumference (590 cm in men and 580 cm in women) [23] . SUA levels significantly increased with the component number of MetS (such as diabetes and hypertension) [24] . In the present study, the incidence of gout in the diabetic population was 21.08/1000 person-years (Table 2) , but a previous study in Taiwan revealed that the incidence of gout was 2.74 (95% CI 2.72, 2.76) per 100 person-years in the general population in 2010 [7] , thus the incidence of gout in the diabetic population was 7.7 times that of the general population. Gout is usually rare in younger adults, but the increasing incidence of gout in younger adults may be related to MetS [25] . Therefore the lower incidence of gout in diabetic populations may be more important than that in general populations.
In the present study, we noted a decreasing trend for new-onset gout after pioglitazone use and a dosedependent risk reduction. Several theories may account for this finding. First, uric acid (UA) under excretion appears to be more severe in gout patients with MetS, and the renal handling of urate in gout patients with MetS has revealed that serum urate levels increase with the severity of MetS, whereas the renal excretion of UA is inversely correlated. This means that the disturbance appears to be related to the severity of MetS [26] . Second, the prevalence of MetS in several rheumatological diseases, including gout, varies from 14 to 62.8%. The treatment of MetS may influence the risk of gout [27] . Gout has been proven to contribute to the high risk of MetS [28] . In contrast, if the prevalence of MetS can be improved, the prevalence of gout may also be improved. In our study, the risk of new-onset gout was reduced by 19% with the use of pioglitazone. Third, our comorbidity stratification using multivariate analysis (Table 4) indicated that pioglitazone users with CAD, CVD and CKD exhibited a non-significant risk reduction for new-onset gout compared with nonpioglitazone users. However, in these subgroups of pioglitazone users with CAD, CVD and CKD, the sample sizes were only 87, 177 and 314, respectively. Additional large-sample studies evaluating these subgroups are needed. TZDs, which are ligands for the transcription factor PPAR-g, modulate glucose and lipid homeostasis, inflammation, cell proliferation and atherosclerosis [29] . PPAR-g represses the expression of inflammatory response genes through a mechanism termed ligand-dependent transrepression, which operates by antagonizing the signal-dependent activation of its target genes through other classes of transcription factors, including nuclear factor kF and AP-1 proteins, thereby inhibiting inflammatory signalling pathways [30] . The key pathogenic processes in gout are monosodium urate crystal formation and deposition. There are potential factors, such as switching from pro-inflammatory to anti-inflammatory macrophages, responsible for the resolution of inflammation in gout of antiinflammatory mediators, including TGF-bG melanocortin and IL-10 [3133]. PPAR-g has two co-activators (gene): 1g (PPARGC1A) and 1n (PPARGC1B) [34] . PPARGC1A and PPARGC1B both express anti-inflammatory properties [35] ; in particular, PPARGC1B inhibits the inflammatory cytokines IL-6 and IL-12 and impedes macrophagemediated inflammation [36] . A recent study indicated that a genetic variant of PPARGC1B is significantly associated with gout and contributes to the pathogenesis of gouty arthritis [37] . The underlying anti-inflammatory mechanism of PPAR-g activator may explain another aspect of decreasing gout incidence with pioglitazone use. However, because of safety issues (increased cancer of the bladder), the use of pioglitazone is still restricted in the European Union and not the first-line therapy for noninsulin-dependent patients [38] . There have been few studies investigating whether TZDs have a direct influence on renal urate excretion. In contrast, improvement in IR by TZDs might decrease UA stone formation by raising urinary pH without changing the urinary excretion of citrate, UA, calcium, oxalate or magnesium [39] .
Although the prevalence of gout is high, the management of gout remains poor [7] . One study in the UK suggested that in 64.9% of allopurinol users, the median length of therapy was 3 months and a high proportion of patients had a medication possession ratio 410%, thus quality-of-care indicators for gout revealed low performance [40] . Other studies have reported that only onefourth to one-third of gout patients were given ULT in the past 2 decades [41] . A study in New Zealand revealed that gout is often suboptimally managed and SUA levels may only be tested when a patient presents with an acute attack of gout [42] . Accordingly, the prevalence of gout has been easily underestimated [4345] . One previous study in the USA revealed that of 437 Campaign Against Cancer and Heart Disease II participants who self- questionnaire [45] . An earlier study in The Netherlands suggested that only 64% of patients with gout selfreported it after 6 months of follow-up [44] . Because of both the poor management of gout and the prevalence of gout being easily underestimated, additional methods for the prevention of gout are required. Because of the high prevalence of gout in MetS patients with high IR, we used pioglitazone as our material for research in a diabetic population. Our study suggested that the pioglitazone user group exhibited a 19% risk reduction (95% CI 0.78, 0.85) for new-onset gout in a diabetic population, and the higher the cumulative DDD of pioglitazone use, the more significant the risk reduction for new-onset gout. Among the diabetic population, pioglitazone users with hypertension or hyperlipidaemia were associated with a significant risk reduction for new-onset gout compared with non-pioglitazone users with these conditions. In contrast, those without hypertension, hyperlipidaemia, CAD, CVD and CKD were associated with a significant risk reduction for new-onset gout compared with nonpioglitazone users.
Limitations
The present study has some limitations. First, this study only demonstrated the preventive effects of pioglitazone for gout in a diabetic population. In general, pioglitazone is not used in non-diabetic populations. Second, the NHI database does not include clinical or laboratory data such as BP, sugar, glycated haemoglobin, high-density lipoprotein and UA levels, therefore we simply based our case definition on the physician-recorded diagnoses instead of ACR criteria [46] or urate crystal identification. Third, an underestimation of the prevalence of gout is easily possible and the length of the observation period was too short, particularly in the diabetic population [43] . Experimental studies or prospective studies for possible anti-inflammatory effects of pioglitazone are necessary.
Conclusions
This cohort study revealed a lower incidence of gout among pioglitazone users than among non-pioglitazone users in a diabetic population. A higher incidence of gout was observed in the diabetic population than in the general population, therefore the prevention of gout in diabetic populations is important. Additional epidemiological studies and biological mechanisms are required to clarify the associations among pioglitazone, IR and gout.
